In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, briefly discusses the possibility of using CAR T-cell therapy in lenalidomide-refractory patients with multiple myeloma (MM). As more patients become triple-class exposed and lenalidomide-refractory, data from the CARTITUDE-4 trial (NCT04181827) suggests that this patient population may benefit significantly from CAR-T therapy. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
